radioimmunoassay and agarose electrophoresis, we found abnormal amounts of this isoenzyme in the serum of 15 of 17 patients with untreated prostatic carcinoma. Among patients with other types of adenocarcinomas and metastatic disease, serum CK-BB was increased in most of those who were unresponsive to therapy. In benign or malignant prostate tissue and in malignant pleural eff usions, cytoplasmic CK-BB as determined by immunoperoxidase staining was found in epithelial cells. Prostatic fluid had high concentrations of CK-BB, as did malignant, but not benign, pleural fluid supernates. We conclude that glandular epithelial cells contain CK-BB, which is released in benign and malignant states and may appear in higher concentrations in the circulation in malignant states. These conclusions are consistent with predictions we have made from a model experimental system concerning characteristics of possible tumor markers. The observations indicate a role for CK-BB as a tumor marker, particularly for adenocarcinoma of the prostate.
Additional Keyphrases:
cancer detection electrophoresis on agarose . radioimmunoassay It is well known that tumor products are often released into the circulation, although exact mechanisms of release remain unclear. Much current emphasis in the search for biological markers has been placed on the so-called oncofetal antigens such as carcinoembryonic antigen (1) and alpha-fetoprotemn (2) . These proteins are present in tumors and fetal tissue, but they are present in only small quantities or are absent in healthy adult tissue. On casual inspection, creatine kinase (EC 2.7.3.2) isoenzyme BB (CK-BB) might be considered to fall into this category because it is the primary form of creatine kinase in fetal muscle (3) and other fetal tissues. However, further investigation into nonmuscle sources of CK-BB reveals that the CK-BB found in the serum of patients with adenocarcinoma (4-7) does not reflect the production of a fetal product by these tumors but instead the retention by tumor cells of an isoenzyme found in normal adult tissue.
Such data are consistent with the information we have gathered through the use of a dynamic model for the detection of possible tumor markers. This model consists of human adenocarcinoma or benign tissue explants, which are maintained viable in organ culture for several days (8) (9) (10) Evidence of CK-BB as a serum marker for malignancy supports these hypotheses. We show here that CK-BB is found in the cytoplasm of both benign and malignant glandular epithelium, and that CK-BB is released from these cells 
Materials and Methods
CK-BB was measured by a sensitive and specific doubleantibody radioimmunoassay (12) . CK-BB purified from human brain was used for raising antibodies in sheep, and for preparing both 1251-labeled tracer and standards. The mean concentration for blood-bank donors and laboratory workers was about 3.5 tg/L, with a 95th percentile of about 6 p.g/L. For this study involving specimens from patients seen at the Good Samaritan Hospital, CK-BB concentration in blood was considered abnormal when it exceeded 10 g/L. Specimens were also analyzed by conventional agarose electrophoresis with fluorescent scanning (11) if the specimens had been stored less than 24 h at 4 #{176}C. In our experience, serum specimens for electrophoresis are stable for only 24 h at 4 #{176}C, Prostatic fluid was obtained from two benign prostate glands after total prostatectomy by sectioning the intact gland and removing the fluid at cut surfaces with a pipette. Pleural fluids were centrifuged and the sedimented cells were stained for CK-BB as described above for tissue sections. The supernatant fluids were assayed for CK-BB content by radioimmunoassay and electrophoretic procedures.
Patients with nonprostatic diseases were grouped according to clinical status as: (a) adenocarcinoma patients without metastatic disease, (b) adenocarcinoma patients with metsstatic disease, and (c) hospitalized patients without cancer. Patients with prostatic disease were grouped as: (a) patients with biopsy-proven benign hypertrophy, (b) patients with biopsy-proven untreated carcinoma according to clinical stage, and (c) patients with biopsy-proven prostatic carcinoma responding to radiation or estrogen therapy, or both. Blood from all patients was drawn once, at the time of clinical evaluation. Table 1 summarizes our data on prostate patients' sera when analyzed for CK-BB by radioimmunoassay. Note that 15 of 17 (89%) patients with untreated prostatic carcinoma had above-normal CK-BB concentrations. By agarose electrophoresis, CK-BB was detected in nine of the 15 specimens that were abnormal by radioimmunoassay; the remaining six abnormal specimens were not suitable because of prolonged storage. Both of the specimens that had normal CK-BB concentration by radioimmunoassay were also negative for CK-BB by electrophoresis. In two of the 15 patients described above, an initial diagnosis of benign prostatic hypertrophy with some atypia was made on the basis of examination of biopsy specimens. On subsequent retropubic prostatectomy, each patient was found to have cancer. In each case, abovenormal serum CK-BB by radioimmunoassay and electrophoresis was observed before biopsy, although tartrate-inhibited acid phosphatase (EC 3.1.3.2) activities were normal.
Results
Eighteen patients with metastatic prostatic carcinoma who were receiving chemotherapy and were in remission did not exhibit supranormal CK-BB by radioimmunoassay or detectable CK-BB by electrophoresis. Thus, in the prostatic patients both methods of CK-BB detection were comparable. Each method was ineffective in detecting one stage B and one stage D patient, but both were effective in correctly identifying other patients with various stages of prostatic carcinoma. Six of 75 patients with biopsy-proven benign prostatic hypertrophy also had increased CK-BB values by radioimmunoassay. These samples were not suitable for electrophoresis. Only one of these six patients subsequently had further surgery, a suprapubic prostatectomy. The tissue revealed some atypia but no evidence of carcinoma. Table 1 also summarizes CK-BB results for patients with other carcinomas besides prostatic and for patients without evidence of cancer (controls). These serum specimens had been frozen and were suitable only for radioimmunoassay. All carcinoma patients with metastases were receiving courses of chemotherapy at the time of serum collection. Twelve of 63 (19%) patients with metastatic disease had increased concentrations of CK-BB. Ten of these 12 were judged to have active disease, i.e., enlarging tumor masses that were not responding to therapy. One other patient with above-normal CK-BB had untreated, estrogen-receptor-negative breast carcinoma, with no evidence of tumor in regional lymph nodes. .. In a, sections were stained for CK-BB snd the dark reaction product is found within the cytoplasm of the malignant epithelium often concentrated at luminal cell surfaces. In b, stainIng of sections is eliminated when CK-BB antisera were preabsorbed with CK-BB from brain. In both a and b, sections were counter-stained with hematoxylin
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Each of the benign prostatic fluids were found to contain approximately 50000 zg of CK-BB per liter by radioimmunoassay, a 10000-fold increase over normal serum. On agarose electrophoresis of these two fluids, more than 98% of the total 
Discussion
CK isoenzymes have become a routine measurement in the clinical laboratory, but primary interest centers around the use of the MB isoenzyme in the diagnosis of myocardial infarction. Several groups have reported the BB isoenzyme to be present in the serum of patients with various malignant (4-7, 11, 15-17) and non-malignant conditions (12, 15, 17) . While the implication has been that CK-BB is produced by tumor cells (6, 16) and enters the serum, strong evidence associating CK-BB with malignant cells has been lacking.
From the data in Table 1 , we conclude that serum immunoreactive CK-BB is associated with untreated or progressive malignant diseases. This is seen in Table 1 in the high percentage of untreated prostatic carcinoma patients with abnormally high concentrations of CK-BB in their serum and in the 12 non-prostatic cancer patients with known metastatic disease who exhibited increased values for CK-BB. Ten of these 12 were clinically evaluated as having active disease that was not responding to therapy. The association with untreated or progressive disease is further supported by the normal CK-BB concentrations in prostatic cancer patients with metastases that are in remission. Also, the presenceof increased serum CK-BB values in patients with several different adenocarcinoma types (Table 1) Six of 75(8%) of patients with benign prostatic hypertrophy had above-normal CK-BB values (Table 1 ). However, two other patients originally with biopsy-based diagnoses of benign prostatic hypertrophy and with increasedCK-BB values were found to have prostatic cancer after total prostatectomy. Thus, above-normal values for CK-BB in patients with a biopsy-based diagnosis of benign prostatic hypertrophy may indicate the need for more extensive evaluations.
The localization of CK-BB by indirect immunohistological methods within the cytoplasm of malignant prostate epithehum and in the cytoplasm of other types of adenocarcinoma cells identifies the probable source of circulating CK-BB in cancer patients. The staining reaction appeared to be antigen-specific because staining was virtually eliminated by preincubating the primary antiserum with CK-BB.
The increased CK-BB in the serum of patients with various adenocarcinomas and in pleural fluids that contain adenocarcinoma cells suggests an association of CK-BB with malignant glandular epithelium. This must be substantiated by further investigation. The presence of increased CK-BB in most malignant but no benign pleural fluids suggests the use of CK-BB as an adjunct to the cytologic or histologic diagnosis of cancer. Again, more data are needed. Also, the increased activity of CK-BB in the bone marrow serum of patients with active osseous metastases (11) might provide a sensitive test of bone involvement.
Since we have demonstrated CK-BB in the cytoplasm of benign prostate epithelium and in prostatic fluid, the presence of serum CK-BB in patients with prostatic cancer follows a prediction derived from our studies of tissue and fluid (8) (9) (10) that secretion products of normal epithelium are likely candidates for serum markers of malignancy in tumors derived from tissue which normally produces and releases these substances. The similar localization of prostatic acid phosphatase and CK-BB in prostate epithelium and prostatic fluid suggests that the simultaneous use of both markers might increase the sensitivity of tumor detection in patients with clinical symptoms of prostate disease and in monitoring prostate cancer patients undergoing chemotherapy.
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